The Management Board of Ryvu Therapeutics S.A. with its registered
office in Krakow, Poland (“Company”, “Issuer”) with reference to current
report No 22/2022 of 5 October 2022, current report No 28/2022 of 2
December 2022, current report No 29/2022 of 7 December 2022, current
report No 31 of 15 December 2022 and current report No 32 of 22 December
2022, provides information regarding the completed subscription of
ordinary bearer series J shares with a nominal value of PLN 0.40 each
(“Series J Shares”).
1. Subscription opening and closing date:
Subscription opening and closing date for retail investors:
– Subscription opening: 8 December 2022 r.
– Subscription closing: 15 December 2022 r.
Subscription opening and closing for institutional investors:
– Subscription opening: 16 December 2022 r.
– Subscription closing: 20 December 2022 r.
Subscription opening and closing for BioNTech SE with its registered
office in Mainz, Germany (the “BioNTech Tranche”):
– Subscription opening: 16 December 2022 r.
– Subscription closing: 21 December 2022 r.
2. Date of allotment of securities:
22 December 2022.
3. Number of securities the subscription applies to:
4,764,674 Series J Shares.
4. Rate of reduction in particular tranches:
The reduction rate of subscriptions submitted by retail investors
without use of the priority right was 55,51 %.
The reduction rate of subscriptions submitted by retail investors with
the use of the priority right – none.
The reduction rate for the institutional investors – none.
The reduction rate in the BioNTech Tranche – none.
5. Number of securities for which subscriptions were submitted:
4,791,361 Series J Shares.
6. Number of securities allotted in the subscription:
4,764,674 Series J Shares.
7. Price at which securities were acquired (subscribed for):
Issue price of one Series J Share for retail and institutional
investors: PLN 55.00.
Issue price of one Series J Share in the BioNTech Tranche: PLN 48.86.
8. The number of persons who subscribed for securities in particular
tranches:
In the subscription for retail investors, 129 persons submitted
subscriptions.
In the subscription for institutional investors, 93 investors submitted
subscriptions.
In the BioNTech Tranche, 1 person submitted a subscription.
9. Number of persons to whom securities were allotted in the
subscription in particular tranches
As part of the allotment to individual and institutional investors, the
Series J Shares were allotted to 222 persons.
In the BioNTech Tranche, the Series J Shares were allotted to 1 person.
10. Name(s) of the underwriters who have taken up securities in the
performance of underwriting agreements, stating the number of securities
they have taken up, together with the actual price per unit of the
security, being the issue or sale price, after deduction of the
consideration for taking up a unit of the security, in the performance
of the underwriting agreement, acquired by the underwriter:
No underwriting agreements were concluded;
11. The value of the conducted subscription, understood as the product
of the number of securities covered by the offer and the issue price:
The value of the conducted subscription amounted to PLN 250,284,006.82.
12. The amount of the total costs which have been included in the costs
of the issue, indicating the amount of the costs by their titles,
divided at least into costs of:
a) preparation and conducting of the offering – PLN 352,628.97
b) remuneration of the underwriters, for each separately – not
applicable;
c) preparation of a prospectus, including costs of advisory services –
PLN 7,153,251.89
d) promoting the offering – none
The costs of issuing series J shares will reduce the Company’s
supplementary capital arising from the excess of the issue value of the
issued shares over their par value. These costs will be recognized in
the financial statements under the reserve capital item.
13. Average cost of conducting the subscription per security unit being
the subject of the subscription – PLN 1.58
14. The method of payment for the securities subscribed (acquired):
All Series J Shares were paid in full in cash.
Zgłoś naruszenie/Błąd
Pozytywnie
Neutralnie 
Negatywnie
Lubię to!
Super
Ekscytujący 
Ciekawy
Smieszny
Smutny
Wściekły
Przerażony
Szokujący
Wzruszający
Rozczarowany
Zaskoczony
Prawda
Manipulacja
Fake news
Oryginalne źródło ZOBACZ
Dodaj kanał RSS
Musisz być zalogowanym aby zaproponować nowy kanal RSS